ZDHHC17 and glioblastoma: By manipulating this specific ZDHHC17-MAP2K4 interaction, we identified genistein as a candidate inhibitor for the ZDHHC17-MAP2K4 signaling module, and provide a potential therapeutic strategy for GBM patients.